93 results found.

Cancer, Solid Tumor Clinical Trial using MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- Phase I Study of Single Agent MK-3475 in Patients With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, and Non-Small Cell Lung Carcinoma.
MK-3475 1 mg/kg; MK-3475 3 mg/kg; MK-3475 10 mg/kg; MK-3475 MEL; MK-3475 NSCLC; MK-3475 MEL Low Dose; MK-3475 MEL High Dose; MK-3475 NSCLC Low Dose; MK-3475 NSCLC High Dose; MK-3475 NSCLC Medium Dose

Cancer, or Solid Tumor Clinical Trial using MK-3475

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors.
MK-3475

Hepatic Complications, Liver Metastases, or Unspecified Adult Sol Clinical Trial using trametinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction.
trametinib; pharmacological study; laboratory biomarker analysis

HIV Infection, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Epithelial Cancer Clinical Trial using Lapatinib; Radiation therapy

Virginia Commonwealth University - Recruiting 18 years or older.
- A Randomized Study of Lapatinib With Radiation Versus Radiation Alone in Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease.
Lapatinib; Radiation therapy

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Speci Clinical Trial using allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune (EBV)-Immune T-Lymphocytes Derived From Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases.
allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

Tumor or Lymphoma Clinical Trial using JNJ-42756493

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma.
JNJ-42756493

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Docetaxel in Patients With Advanced Solid Tumors..
PI3K inhibitor BKM120; docetaxel; pharmacological study; questionnaire administration; laboratory biomarker analysis

Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Ne Clinical Trial using questionnaire administration; cognitive assessment; psychosocial assessment and care; quality-of-life assessment

Children's Oncology Group - Recruiting 1 Month to 21 years.
- Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer.
questionnaire administration; cognitive assessment; psychosocial assessment and care; quality-of-life assessment

Malignant Solid Neoplasms Clinical Trial using Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD)

Centre Leon Berard - Recruiting 18 years or older.
- A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors.
Nilotinib (400 mg BID); Everolimus (10 mg QD); Sorafenib (400 mg BID); Lapatinib (1500 mg QD); Pazopanib (800 mg QD)

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of Oral Calcitriol With Fixed Dose of Cisplatin and Gemcitabine in Patients With Advanced Solid Tumors.
calcitriol; cisplatin; gemcitabine hydrochloride; pharmacological study

Solid Tumors, or Metastatic Disease Clinical Trial using Histological biopsy procedure

UMC Utrecht - Recruiting 18 years or older.
- Protocol to Obtain Tumor Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer to Improve Selection for Clinical Trials. (CPCT - 05 Biopsy Protocol Patient Selection).
Histological biopsy procedure

Adult Acute Lymphoblastic Leukemia in Remission, Adult Nasal Type Clinical Trial using dasatinib; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction.
dasatinib; pharmacological study

Cancer, or Advanced Solid Tumors Clinical Trial using Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)

VU University Medical Center - Recruiting 18 years or older.
- Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies..
Sunitinib; Sorafenib; Erlotinib; Everolimus; Lapatinib; Dasatinib; Pazopanib; Vemurafenib; tumor biopsy; skin biopsy (optional)

Solid Tumor, or Non-small Cell Lung Cancer Clinical Trial using MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Merck Sharp & Dohme Corp. - Recruiting 20 years or older.
- A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Cisplatin/Pemetrexed or Carboplatin/Paclitaxel in Subjects With Advanced Non-Small Cell Lung Cancer.
MK-3475; Cisplatin; Pemetrexed; Carboplatin; Paclitaxel

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, or Desmoplastic Small Clinical Trial using Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 35 years.
- A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias.
Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

Solid Tumor, Leukemia, or Neurofibromatosis Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 6 years or older.
- Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults With Chronic Illness and Their Parents.

Solid Tumors, Brain Tumors, Sarcoma, Wilm's Tumor, or Rhabdomyosa Clinical Trial using NK cellular therapy; rhIL-15

National Institutes of Health Clinical Center (CC) - Recruiting 2 years to 29 years.
- A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors.
NK cellular therapy; rhIL-15

Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant, or Clinical Trial using NHS-IL-12

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- First In-Human Phase I Trial of NHS-IL12 in Subjects With Metastatic Solid Tumors.
NHS-IL-12

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using vismodegib; sirolimus; positron emission tomography; computed tomography; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18

Mayo Clinic - Recruiting 18 years or older.
- Phase I Trial of The Combination of Vismodegib and Sirolimus.
vismodegib; sirolimus; positron emission tomography; computed tomography; pharmacological study; laboratory biomarker analysis; fludeoxyglucose F 18

Colorectal Neoplasms, Gastric Neoplasms, Cholangiocarcinoma, Bile Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors.

Neuroblastoma;, Rhabdomyosarcoma;, Ewing's Sarcoma;, Ewing's Tumo Clinical Trial using nab-paclitaxel

Celgene Corporation - Recruiting 6 Months to 21 years.
- A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
nab-paclitaxel

Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Clinical Trial using DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors.
DEC-205-NY-ESO-1 fusion protein vaccine; sirolimus; laboratory biomarker analysis

Neoplasm Malignant Clinical Trial using SAR566658

Sanofi - Recruiting 18 years or older.
- Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Adult Patients With CA6-Positive and Refractory Solid Tumors.
SAR566658

Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic T Clinical Trial using alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

St. Jude Children's Research Hospital - Recruiting 2 years to 21 years.
- A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas.
alemtuzumab; fludarabine; sirolimus; Busulfan; melphalan; stem cells

Solid Tumor Clinical Trial using Oraxol

Kinex Pharmaceuticals Inc - Recruiting 18 years or older.
- A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies.
Oraxol

Solid Tumors, or Advanced Cancer Clinical Trial using Anastrozole; Bevacizumab; Everolimus; Sorafenib; Erlotinib

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance.
Anastrozole; Bevacizumab; Everolimus; Sorafenib; Erlotinib

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using veliparib; mitomycin C; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair.
veliparib; mitomycin C; laboratory biomarker analysis

Thrombocytopaenia Clinical Trial using Eltrombopag olamine; Placebo

GlaxoSmithKline - Recruiting 18 years or older.
- A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin.
Eltrombopag olamine; Placebo

Neoplasm Malignant Clinical Trial using Cabazitaxel (XRP6258)

Sanofi - Recruiting 18 years or older.
- Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients With Varying Degrees of Hepatic Impairment.
Cabazitaxel (XRP6258)

Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Clinical Trial using Rucaparib

Clovis Oncology, Inc. - Recruiting 18 years or older.
- A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor.
Rucaparib

Herpes Zoster Clinical Trial using V212; Placebo

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy.
V212; Placebo

Melanoma, Metastatic Melanoma, or Solid Tumor Clinical Trial using MLN2480

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion Phase in Patients With Metastatic Melanoma.
MLN2480

Breast Neoplasms Clinical Trial using Sorafenib (Nexavar, BAY43-9006); Eribulin

Bayer - Recruiting 18 years or older.
- A Phase 1, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination With Eribulin in Subjects With Advanced, Metastatic or Refractory Solid Tumors.
Sorafenib (Nexavar, BAY43-9006); Eribulin

BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, or Unspecified Ad Clinical Trial using veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase 1 Trial of ABT-888 and SCH727965 Without or With Carboplatin in Patients With Advanced Solid Tumors.
veliparib; dinaciclib; carboplatin; laboratory biomarker analysis; pharmacological study

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma and Other Solid Tumors.
dabrafenib; trametinib; navitoclax; pharmacological study; laboratory biomarker analysis

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using dabrafenib; pazopanib hydrochloride; Correlative studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors.
dabrafenib; pazopanib hydrochloride; Correlative studies

Advanced Solid Tumor, or Lymphomas Clinical Trial using LEE011

Novartis - Recruiting 18 years or older.
- A phase1 Multi-center, Open Label, Dose-escalation Study of Oral LEE011 in Patients With Advanced Solid Tumors or Lymphoma.
LEE011

Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Clinical Trial using veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy.
veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

Congenital Combined Immunodeficiency, Fungal Infection, Hematopoi Clinical Trial using caspofungin acetate; fluconazole; voriconazole; laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 20 years.
- A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT).
caspofungin acetate; fluconazole; voriconazole; laboratory biomarker analysis

Advanced Solid Tumor, or Lymphoma Clinical Trial using DS-3032

Daiichi Sankyo Inc. - Recruiting 18 years or older.
- A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas.
DS-3032

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using nanosomal docetaxel lipid suspension; pharmacological study

USC/Norris Comprehensive Cancer Center - Recruiting 18 years to 64 years.
- An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors.
nanosomal docetaxel lipid suspension; pharmacological study

Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Can Clinical Trial using DCVax-Direct

Northwest Biotherapeutics - Recruiting 18 years to 75 years.
- A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS.
DCVax-Direct

CANCER, NOS Clinical Trial using Lirilumab; Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors.
Lirilumab; Ipilimumab

Spinal Cord Compression, or Unspecified Adult Solid Tumor, Protoc Clinical Trial using radiation therapy

ICORG- All Ireland Cooperative Oncology Research Group - Recruiting 18 years or older.
- A Randomised Phase III Trial of Two Fractionation Schemes in the Treatment of Malignant Spinal Cord Compression.
radiation therapy

Adult Primary Liver Cancer, or Kidney Tumor Clinical Trial using ultrasound elasticity imaging

Stanford University - Recruiting 19 years or older.
- US Elastography for Characterizing Focal Lesions in the Liver and Kidney.
ultrasound elasticity imaging

Solid Tumor and Hematologic Malignancies Clinical Trial using MEK162

Novartis - Recruiting 18 years or older.
- Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors.
MEK162

Hepatic Complications, Renal Failure, or Unspecified Adult Solid Clinical Trial using dabrafenib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction.
dabrafenib; pharmacological study; laboratory biomarker analysis

Advanced Solid Tumor Diseases Clinical Trial using Individual Meaning-Centered Psychotherapy (IMCP); standard Individual Supportive Psychotherapy (ISP); enhanced usual care (EUC)

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years or older.
- A Randomized Controlled Trial of Individual Psychosocial Interventions for Cancer Patients.
Individual Meaning-Centered Psychotherapy (IMCP); standard Individual Supportive Psychotherapy (ISP); enhanced usual care (EUC)

Solid Tumor, Malignant Hematological Tumor, or Primary or Seconda Clinical Trial

Hospira, Inc. - Recruiting N/A or older.
- The Compatibility of Nivestim(TM) Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases.

Tumor, Solid Clinical Trial using MK-8353

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 (Formerly SCH 900353) in Subjects With Advanced Solid Tumors (Protocol No. 001 (Formerly P06203)).
MK-8353

Cancer, Solid Tumor, or Hematologic Malignancy Clinical Trial

City of Hope Medical Center - Recruiting 65 years or older.
- Delivering the Geriatric Assessment Tool to Older Adults With Cancer Using Computer Survey Methodologies: Testing Feasibility, Reliability, and Validity of Research Electronic Data Capture (REDCap) and Support Screen (Touchscreen) Technologies.

Solid Tumor, or Anaplastic Thyroid Cancer Clinical Trial using Cisplatin and Crolibulin; Cisplatin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 90 years.
- A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC).
Cisplatin and Crolibulin; Cisplatin

Breast Cancer, or Unspecified Adult Solid Tumor, Protocol Specifi Clinical Trial using positron emission tomography/computed tomography; fludeoxyglucose F 18; PET/MRI; gadopentetate dimeglumine; questionnaire administration

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Positron Mammographic Imaging (PMI).
positron emission tomography/computed tomography; fludeoxyglucose F 18; PET/MRI; gadopentetate dimeglumine; questionnaire administration

Tumors Metastatic to Brain, or Unspecified Adult Solid Tumor Clinical Trial using stereotactic radiosurgery; quality-of-life assessment; cognitive assessment

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- Dose Escalation for Larger Brain Metastases: Phase I/II Study.
stereotactic radiosurgery; quality-of-life assessment; cognitive assessment

Advanced Solid Tumor Clinical Trial using INC280

Novartis - Recruiting 18 years or older.
- A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors.
INC280

Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medul Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 18 years.
- A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Advanced Solid Tumor Clinical Trial using LDE225; Wafarin; Bupropion

Novartis - Recruiting 18 years or older.
- A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors.
LDE225; Wafarin; Bupropion

Malignant Solid Tumor - Malignant Nervous System Neoplasm Clinical Trial using Cabazitaxel (XRP6258)

Sanofi - Recruiting 2 years to 18 years.
- A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System.
Cabazitaxel (XRP6258)

Advanced Solid Tumor and Lymphoma Malignancies Clinical Trial using TAK-659

Millennium Pharmaceuticals, Inc. - Recruiting 18 years or older.
- An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies.
TAK-659

Solid Tumor Clinical Trial using MSC2363318A

EMD Serono - Recruiting 18 years or older.
- A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies.
MSC2363318A

Solid Tumor Malignancies Clinical Trial using Clostridium novyi-NT spores

BioMed Valley Discoveries, Inc - Recruiting 18 years or older.
- Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies.
Clostridium novyi-NT spores

Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nau Clinical Trial using Real Acupressure Band; Placebo Acupressure Band

University of South Florida - Recruiting 4 years to 18 years.
- Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy.
Real Acupressure Band; Placebo Acupressure Band

Solid Tumor Clinical Trial using RX-3117

Rexahn Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies.
RX-3117

Cancer, Infection, Inflammation, Tumor, Sarcoid, or Lymphadenopat Clinical Trial

University of Minnesota - Clinical and Translational Science Institute - Recruiting 18 years or older.
- Comparison of 'Wet Suction' Technique to Contemporary 'Dry Suction' Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial.

Hematopoietic/Lymphoid Cancer, or Unspecified Adult Solid Tumor, Clinical Trial using questionnaire administration; quality-of-life assessment

City of Hope Medical Center - Recruiting 18 years or older.
- Physical, Emotional and Social Stressors and Their Impact on Quality of Life of Caregivers of Hospitalized Older Adults With Cancer.
questionnaire administration; quality-of-life assessment

Cancer Clinical Trial using GSK1120212B (Standard DMSO content); GSK1120212B (Lower DMSO content)

GlaxoSmithKline - Recruiting 18 years or older.
- An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies.
GSK1120212B (Standard DMSO content); GSK1120212B (Lower DMSO content)

Lung Cancer, or Solid Tumor (Not Breast or Prostate Cancers) Clinical Trial using Cabozantinib

Massachusetts General Hospital - Recruiting 18 years or older.
- Phase II Trial of Cabozantinib (XL184) in Patients With Advanced Solid (Non-breast, Non-prostate) Malignancies and Bony Metastases.
Cabozantinib

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using methoxyamine; temozolomide; DNA analysis; laboratory biomarker analysis; pharmacological study

Case Comprehensive Cancer Center - Recruiting 18 years or older.
- A Phase I Study of Methoxyamine and Temozolomide in Patients With Advanced Solid Tumors.
methoxyamine; temozolomide; DNA analysis; laboratory biomarker analysis; pharmacological study

Ovarian Cancer, Peritoneal Cavity Cancer, or Unspecified Adult So Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; liquid chromatography; mass spectrometry; pharmacological study; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 19 years or older.
- Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity.
paclitaxel albumin-stabilized nanoparticle formulation; liquid chromatography; mass spectrometry; pharmacological study; laboratory biomarker analysis

Metastatic Cancer, or Unspecified Adult Solid Tumor, Protocol Spe Clinical Trial using bevacizumab; quality-of-life assessment

Northwestern University - Recruiting 18 years or older.
- A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy.
bevacizumab; quality-of-life assessment

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial using tivantinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 21 years.
- A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors.
tivantinib; pharmacological study; laboratory biomarker analysis

Advanced Solid Tumor Clinical Trial using BYL719

Novartis - Recruiting 18 years or older.
- A Study of BYL719 in Adult Patients With Advanced Solid Malignancies.
BYL719

Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Sta Clinical Trial using riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Riluzole and Sorafenib in Patients With Advanced Solid Tumors and Melanoma.
riluzole; sorafenib tosylate; diagnostic laboratory biomarker analysis; pharmacological study

Advanced Cancer, or Solid Tumor Clinical Trial using Vemurafenib; Everolimus; Temsirolimus

M.D. Anderson Cancer Center - Recruiting N/A or older.
- A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelborafr) in Combination With an mTOR Inhibitor, Everolimus (Afinitorr) or Temsirolimus (Toriselr), in Subjects With Advanced Cancer.
Vemurafenib; Everolimus; Temsirolimus

Solid Tumor Clinical Trial using ARQ 087

ArQule - Recruiting 18 years or older.
- A Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors.
ARQ 087

Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcin Clinical Trial using alisertib; gemcitabine

University of California, Davis - Recruiting 18 years or older.
- Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer.
alisertib; gemcitabine

Advanced Cancers (Solid Tumors) Clinical Trial using GL-ONC1

Genelux Corporation - Recruiting 18 years or older.
- Phase I Study of the Safety, Tolerability,and Tumor-Specific Replication of the Intravenous Administration of Green Fluorescent Protein Encoded Genetically Engineered Attenuated Vaccinia Virus, GL-ONC1, in Patients With Advanced Solid Organ Cancers..
GL-ONC1

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial using carboplatin; cyclophosphamide; etoposide phosphate; gene expression analysis; polymorphism analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting N/A to 2 years.
- Pharmacokinetics and Pharmacogenetics of Anticancer Drugs in Infants and Young Children.
carboplatin; cyclophosphamide; etoposide phosphate; gene expression analysis; polymorphism analysis; pharmacological study

Fatigue, or Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using exercise

University of Rochester - Recruiting 21 years or older.
- A Study of the Effects of Exercise on Cancer-Related Fatigue.
exercise

Chemotherapeutic Agent Toxicity, Sarcoma, or Unspecified Childhoo Clinical Trial using gene expression analysis; polymorphism analysis; management of therapy complications

National Cancer Institute (NCI) - Recruiting N/A to 20 years.
- CYP3A5 Genotype as a Potential Risk Factor for the Development of Ifosamide Nephrotoxicity in Children.
gene expression analysis; polymorphism analysis; management of therapy complications

Glioma, Neuroectodermal Tumors, Primitive, Wilms Tumor, Rhabdomyo Clinical Trial using Metronomic Cyclophosphamide; Thalidomide

Washington University School of Medicine - Recruiting 5 years to 21 years.
- Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Relapsed and Refractory Pediatric Solid Tumors.
Metronomic Cyclophosphamide; Thalidomide

Malignant Solid Tumour, Breast Cancer Nos Metastatic Recurrent, o Clinical Trial using Eribulin in Combination w/ Cyclophosphamide

University of California, San Francisco - Recruiting 18 years to 80 years.
- A Phase Ib/II Study of Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies.
Eribulin in Combination w/ Cyclophosphamide

Solid Tumor, or Liver Metastases Clinical Trial using stereotactic body radiotherapy-photon; Stereotactic body radiotherapy-proton

Massachusetts General Hospital - Recruiting 18 years or older.
- Phase II Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases.
stereotactic body radiotherapy-photon; Stereotactic body radiotherapy-proton

Cancer Survivor, Cardiovascular Complications, Hematopoietic/Lymp Clinical Trial using questionnaire administration; laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 21 years.
- Key Adverse Events After Childhood Cancer.
questionnaire administration; laboratory biomarker analysis

Adult Solid Tumor, Adenocarcinoma of the Colon, Adenocarcinoma of Clinical Trial using PD-0332991; pharmacological study

Abramson Cancer Center of the University of Pennsylvania - Recruiting 18 years or older.
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer.
PD-0332991; pharmacological study

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study

Pancreatic Tumor, Gastric Tumor, Esophageal Tumor, Lymphadenopath Clinical Trial using Endoscopic ultrasound guided needle tissue acquisition.

Stony Brook University - Recruiting 18 years or older.
- Comparing the Overall Efficacy of Endoscopic Ultrasound Fine Needle Aspiration Versus Fine Needle Biopsy in the Diagnosis of Solid Lesions: A Multicenter, Randomized Clinical Trial.
Endoscopic ultrasound guided needle tissue acquisition.

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial using hydroxychloroquine; temozolomide; TdT-mediated dUTP nick end labeling assay; western blotting; electron microscopy; high performance liquid chromatography; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; mass spectrometry; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Study of Hydroxychloroquine in Combination With Temozolomide in Patients With Advanced Solid Tumors.
hydroxychloroquine; temozolomide; TdT-mediated dUTP nick end labeling assay; western blotting; electron microscopy; high performance liquid chromatography; immunoenzyme technique; immunohistochemistry staining method; laboratory biomarker analysis; mass spectrometry; pharmacological study

Cancer, Solid Tumor, or Hematologic Malignancy Clinical Trial

Community Cancer Care - Recruiting 18 years or older.
- Home-Based Symptom Monitoring: Its Impact on Cancer Care Team Behaviors and Patient Outcomes.